272 completed, 82 unknown, 37 recruiting, 35 terminated. 482 Phase 3, 93 Phase 2.
Follow Pathological Conditions, Anatomical: new trials by email Literature Review of Pathological Conditions, Anatomical trials Research Report on Pathological Conditions, Anatomical
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Oral Minoxidil (N1087) in Men With Androgenetic Alopecia. Minoxidil oral solution, Placebo oral solution - Androgenetic Alopecia, Androgenetic Alopecia (AGA) | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-31 | 2026-11-06 |
| Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss DA-005, Topical minoxidil 5%, DA-002 - Androgenetic Alopecia, Female Pattern Baldness | Phase 3 | Withdrawn | Applied Biology, Inc. | 2027-01-15 | 2026-11-02 | |
| Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of N1087 in Participants With Female Pattern Hair Loss (MINORA-WOMEN) N1087, Placebo - Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 372 | 2027-01-01 | 2026-11-04 |
| Efficacy of Botulinum Toxin A Versus Nanofat in the Treatment of Androgenetic Alopecia: A Comparative Clinical Trial Botulinum Toxin Type A, Autologous Nanofat Injection - Androgenetic Alopecia | Phase 2 / Phase 3 | Not yet recruiting | Sherief Ayman Hussein Shaamash | 40 | 2026-12-01 | 2026-10-07 |
| Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis 0.412% stannous fluoride toothpaste and flat trimmed toothbrush, 0.76% Na MFP and flat trimmed toothbrush - Plaque, Gingivitis | Phase 3 | Completed | Colgate Palmolive | 84 | 2026-10-09 | 2026-11-10 |
| Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia APSMNF 1, APSMNF 2, Eniagor® - Alopecia, Androgenetic | Phase 3 | Not yet recruiting | Apsen Farmaceutica S.A. | 336 | 2026-10-07 | 2026-09-08 |
| NanoSALV vs Standard Topical Care Pathway in Sports-Related Skin Lesions NanoSALV Catalytic, Standard Topical Care Pathway - Blister of Foot, Blister | Phase 3 | Not yet recruiting | Shahab Alizadeh | 100 | 2026-10-01 | 2026-09-08 |
| Clinical Study Examining the Control of Plaque and Gingivitis Silica Free Meridol, Meridol, Colgate Dental Product - Gingivitis | Phase 3 | Not yet recruiting | Colgate Palmolive | 135 | 2026-10-01 | 2026-09-25 |
| A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) GSK5784283, Placebo, Standard of Care - Nasal Polyps | Phase 3 | Recruiting | GlaxoSmithKline | 218 | 2026-09-28 | 2026-11-17 |
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males PP405 0.05% Topical Gel, Vehicle Topical Gel - Androgenetic Alopecia | Phase 2 / Phase 3 | Recruiting | Pelage Pharmaceuticals, Inc. | 600 | 2026-09-21 | 2026-11-19 |
| A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) GSK5784283, Placebo, Standard of Care - Nasal Polyps | Phase 3 | Recruiting | GlaxoSmithKline | 218 | 2026-09-03 | 2026-11-16 |
| Clinical Evaluation of a Toothpaste for Dental Plaque Reduction and Prevention of Gum Problems 0.45% SnF HW with NaF (1450 F), 67% Bicarbonate with NaF (1400 F), Colgate Cavity Protection Toothpaste - Plaque, Dental Plaque | Phase 3 | Recruiting | Colgate Palmolive | 120 | 2026-07-20 | 2026-09-25 |
| Trial to Assess the Efficacy of EMPAgliflozin and Personalized Dietary Counseling for Kidney STONE Prevention Empagliflozin 10 MG, Placebo, Personalized dietary counseling - Kidney Stone, Nephrolithiasis | Phase 3 | Recruiting | Insel Gruppe AG, University Hospital Bern | 400 | 2026-07-02 | 2026-10-23 |
| Baxdrostat and Ventricular Remodeling Baxdrostat, Placebo - Cardiac Remodeling | Phase 3 | Not yet recruiting | Subodh Verma | 286 | 2026-06-30 | 2026-06-17 |
| Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata Deuruxolitinib, Placebo - Alopecia Areata | Phase 3 | Recruiting | Sun Pharma Japan Limited | 78 | 2026-06-19 | 2026-10-30 |
| A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). Donanemab, Placebo - Alzheimer Disease, Dementia | Phase 3 | Recruiting | Eli Lilly and Company | 550 | 2026-05-22 | 2026-10-28 |
| Adjuvant Steroid Outcomes in Idiopathic Subglottic Stenosis Triamcinolone 0.1%, Placebo - Idiopathic Subglottic Stenosis | Phase 3 | Recruiting | Johns Hopkins University | 226 | 2026-05-20 | 2026-11-12 |
| Study to Investigate Toothpaste on Antibacterial Effects in the Different Regions of the Mouth stannous fluoride toothpaste, 0.76% Sodium Monofluorophosphate (Na MFP) toothpaste - Plaque, Gingivitis | Phase 3 | Completed | Colgate Palmolive | 95 | 2026-05-18 | 2026-09-24 |
| Clinical Study of DA-001 as a Treatment for Hair Shedding Reduction and Hair Re-Growth DA-001, Placebo, Phenylephrine - Telogen Effluvium, Female Pattern Hair Loss | Phase 2 / Phase 3 | Not yet recruiting | Applied Biology, Inc. | 1120 | 2026-05-01 | 2026-04-13 |
| Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP) | Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 168 | 2026-04-08 | 2026-05-11 |
Showing 20 of 482. Sign in to see all of them.
Alopecia (55) · Plaque, Amyloid (47) · Nasal Polyps (34) · Sarcopenia (24) · Intervertebral Disc Displacement (22) · Hernia (21) · Kidney Calculi (20) · Dilatation, Pathologic (19) · Muscular Atrophy (19) · Pelvic Organ Prolapse (19) · Hernia, Inguinal (18) · Hypertrophy, Left Ventricular (18) · Gingivitis (16) · Constriction, Pathologic (15) · Atrophy (14)
Pathological Conditions, Signs and Symptoms (482) · Signs and Symptoms (99) · Pathologic Processes (88) · Nervous System Diseases (78) · Skin and Connective Tissue Diseases (78) · Neurologic Manifestations (76) · Skin Diseases (69) · Urogenital Diseases (64) · Female Urogenital Diseases and Pregnancy Complications (63) · Hernia (62) · Female Urogenital Diseases (61) · Cardiovascular Diseases (59) · Digestive System Diseases (59) · Hypotrichosis (54)
Minoxidil (16) · Bupivacaine (11) · secukinumab (11) · Sodium Chloride (9) · Mometasone Furoate (8) · Saline Solution (8) · Solutions (7) · Standard of Care (7) · Tamsulosin (6) · Atorvastatin (5) · Dutasteride (5) · Lidocaine (5) · Ospemifene (5) · Pregabalin (5) · Riboflavin (5)
Novartis Pharmaceuticals (21) · Colgate Palmolive (13) · GlaxoSmithKline (11) · Assistance Publique - Hôpitaux de Paris (7) · University of Erlangen-Nürnberg Medical School (7) · Pfizer (6) · Eli Lilly and Company (5) · Organon and Co (5) · Shionogi (5) · AstraZeneca (4) · Eisai Inc. (4) · Erasmus Medical Center (4) · Applied Biology, Inc. (3) · Eurofarma Laboratorios S.A. (3) · Hoffmann-La Roche (3)
United States (184) · Germany (60) · France (59) · Canada (58) · Italy (46) · Spain (45) · United Kingdom (44) · Japan (38) · Poland (36) · China (33) · Netherlands (33) · Belgium (31) · Australia (26) · Russia (26) · Czechia (22)
Wolfgang Kemmler, PhD (4) · Andy Goren, MD (3) · Reid Waldman, M.D. (3) · Timothy Durso, M.D. (3) · Willi A Kalender, PhD (3) · Alessandro Mazzetti, M.D. (2) · Frederik Nevens, MD, PhD (2) · J.F. Lange, professor (2)
PMID 33710614, PMID 33548517, PMID 35305260, PMID 37341961, PMID 37951571, PMID 38197558, PMID 41743463, PMID 15933795, PMID 18591942, PMID 25013998, PMID 26507877, PMID 27138015, PMID 27573260, PMID 27576559, PMID 32791950, PMID 33275766, PMID 33345059, PMID 33748660, PMID 34110605, PMID 34289971, PMID 34382434, PMID 36567000, PMID 37214171, PMID 38263353, PMID 38825327, PMID 39356039, PMID 39962358, PMID 40037388, PMID 41461999, PMID 41917311, PMID 42481842, PMID 42823604, PMID 10360498, PMID 11403367, PMID 12172314, PMID 12423712, PMID 12621133, PMID 12719068, PMID 12756590, PMID 12790869, PMID 14598268, PMID 14630977, PMID 14639093, PMID 14700505, PMID 14704728, PMID 14744931, PMID 15107485, PMID 15253184, PMID 15253732, PMID 15647341
2017 (7), 2016 (4), 2015 (3), 2018 (3), 2023 (3), 2008 (2), 2009 (2), 1UG3HL173394-01A1 (1), 2014 (1), 2025 (1), K23HL078901 (1), R01AG021570 (1), R01CA098286 (1), R01DK062030 (1), R01NR004007 (1)